When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
Amgen released more encouraging data on the late-stage developmental drug Prolia for bone loss in cancer patients. Onyx Pharmaceuticals unveiled positive breast cancer test results with its drug Nexavar. OSI Pharmaceuticals presented promising numbers in a couple of lung cancer patient subgroups with its pill Tarceva. And on the deal side BioCryst Pharmaceuticals announced the government is giving the company another $77 million to finish testing on its experimental, injectable flu-fighter peramivir. AstraZeneca said it's teaming up with the previously left-for-dead Nektar Therapeutics. And even Dell's deal for Perot Systems is moving some healthcare-related stocks.